Abstract
Dendritic cells (DC) exert important functions both in the induction of protective T cell immunity, as well as in the induction of tolerance. The latter is essential in protection against the development of allergy. Exposure to pathogenassociated molecular patterns (PAMPs), that signal through different Toll-like receptor (TLR)s, modulates production by DC of several Interleukin(IL)-12 family members: IL-12p70, IL-23, IL-27 and IL-35. The production of those cytokines in turn differentially influences both T cell differentiation and effector T cell activation. We focus in this review on myeloid and plasmacytoid DC and their role in development of allergic diseases. In particular, we focus on differences in DC activation between healthy and allergic individuals. Furthermore we discuss the activation of DC by TLR-ligands and their differential cytokine induction. Finally, we discuss preclinical studies and potentially therapeutic options using TLRligands for allergic diseases.
Keywords: Dendritic cell, T cell, toll-like receptor, Th1, Th2, Th17
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Influence of Toll-Like-Receptor Ligands on the Dendritic Cell - T Cell Interactions: Therapeutic Options for Allergic Diseases? Mini-Review
Volume: 7 Issue: 4
Author(s): Dominique M.A. Bullens and Jan L. Ceuppens
Affiliation:
Keywords: Dendritic cell, T cell, toll-like receptor, Th1, Th2, Th17
Abstract: Dendritic cells (DC) exert important functions both in the induction of protective T cell immunity, as well as in the induction of tolerance. The latter is essential in protection against the development of allergy. Exposure to pathogenassociated molecular patterns (PAMPs), that signal through different Toll-like receptor (TLR)s, modulates production by DC of several Interleukin(IL)-12 family members: IL-12p70, IL-23, IL-27 and IL-35. The production of those cytokines in turn differentially influences both T cell differentiation and effector T cell activation. We focus in this review on myeloid and plasmacytoid DC and their role in development of allergic diseases. In particular, we focus on differences in DC activation between healthy and allergic individuals. Furthermore we discuss the activation of DC by TLR-ligands and their differential cytokine induction. Finally, we discuss preclinical studies and potentially therapeutic options using TLRligands for allergic diseases.
Export Options
About this article
Cite this article as:
Bullens M.A. Dominique and Ceuppens L. Jan, Influence of Toll-Like-Receptor Ligands on the Dendritic Cell - T Cell Interactions: Therapeutic Options for Allergic Diseases? Mini-Review, Inflammation & Allergy - Drug Targets (Discontinued) 2008; 7 (4) . https://dx.doi.org/10.2174/187152808786848397
DOI https://dx.doi.org/10.2174/187152808786848397 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology Alzheimers Disease and Intelligence
Current Alzheimer Research Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action
Current Pharmaceutical Design Epigenetics in Clinical Management of Children and Adolescents with Brain Tumors
Current Cancer Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Editorial [Is Drug Safety Dangerous?]
Current Drug Safety Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders
Current Molecular Medicine Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease
Current Topics in Medicinal Chemistry Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics